Breaking News

Financial Report: Johnson & Johnson

January 22, 2013

Revenues up 8% in the quarter

Johnson & Johnson
 
4Q Revenues: $17.6 billion (+8%)

4Q Earnings: $2.6 billion (earnings were $218 million in 4Q12)

YTD Revenues: $67.2 billion (+3%)

YTD Earnings: $10.5 billion (+9%)

Comments: Pharmaceutical sales were $6.5 billion in the quarter, up 7%, and $25.4 billion for the year, up 4%. Remicade sales were $1.5 billion in the quarter, up 5% and $6.1 billion for the year, up 12%. Simponi sales were up 52% to $181 million in the quarter, and up 48% to $607 million for the year. Stelara sales were $269 million in the quarter, up 30%, and $1.0 billion for the year, up 39%. Risperdal Consta sales were down 7% to $358 million in the quarter, and down 10% for the year to $1.4 billion. Velcade sales were up 43% in the quarter and 18% for the year to $502 million and $1.5 billion, respectively. Consumer sales were flat at $3.7 billion in the quarter, and up 3% for the year, to $14.4 billion. Medical Devices and Diagnostics revenue was $7.4 billion in the quarter, up 14%, and $27.4 billion for the year, up 6%. 2012 results included $4.2 billion charges for product liability expenses, litigation, and costs associated with the DePuy Hip recall.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision